MH: What impact will the political change in Washington have on the health IT world? MH: Will MACRA implementation boost your business?

into the source EHR, whether it’s Cerner, Epic or Allscripts.

From a consumer standpoint, if you’re a physician, this data has to be presented to you in the workflow of your practice. I just want to see what’s relevant to this patient in front of me. This is why we believe our population health layer, our interoperable layer, is more robust and has better outcomes for our large clients.

MH: Who’s a major client who has used your platform in that way?

Black: Baylor, Scott & White Health in Dallas. They have six different health plans they work with, one of which is owned by Baylor; they have 50 different electronic health record systems. They have the Allscripts system in the Dallas area and further south they have Epic.

The platform sits on top of all of those EHRs and does the connections, the harmonization, the analytics, and the transactions that are created to go back down to 50 systems.

MH: What will be the big issues at HIMSS this year?

Black: Interoperability continues to be the big issue. There’s been a fair amount of automation, but as a consumer, you’re not able to get your own data.

It is crucial to care coordination, which is a subset of population health. How do I handle a patient in the ambulatory, acute and post-acute situation? How do we manage patients as they go from organization to organization?

There will be a continued focus on the consumer, with cool apps that people are building to live on top of the basic EHR framework. In the past three years, we’ve finished paving the interstate across the entire U.S. Now lots of people are going to take advantage of that digital framework.

The other theme we’re working on is precision medicine. We combine information that comes from sequencing machines with information from the EHR on family history, current meds, their conditions. How do you manage the phenotypic information to build the absolute best, most precise protocol that would give the best outcome for that particular human as they’re dealing with a serious illness?

MH: How does the partnership with Nant fit in?

Black: We have a way to identify which patients should be sequenced and to figure out how to translate that into a protocol based on that information. There’s a fair amount of intellectual property we’ve developed that will make that workflow more usable, not only by large academic medical centers, but for the large ambulatory population of clients that we have. We want to make that new science available to folks not just in large populated areas, but in Des Moines, Cedar Rapids and other places across the country that haven’t historically had a 30-story academic medical center.

MH: Is this strictly about cancer?

Black: The moonshot is about compressing the time between discovery and the clinic. That involves the National Institutes of Health, the Food and Drug Administration, drug companies … to help find patients more expeditiously for clinical trials. It’s a pretty broad collaboration. The price of sequencing coming down has created the energy behind the cancer moonshot. We think capabilities are here today that weren’t here three or four or five years ago.

The FDA says we’re very interested in helping you with smaller trials. But we want to make sure that we get this out to middle America, to rural America as quickly as we do to Dana Farber. How do we close the loop for people in rural areas who should also have access to these new medical protocols?

We have a huge primarycare network—45,000 physicians spread out across the U.S., mostly in four- to six-doc practices. That’s where we can get the identification and surveillance of some of these rare diseases. They couldn’t afford the three- or four-hour car ride to go to participate in a clinical trial. I don’t think it will be solved overnight. But if done correctly, it can have a very broad impact.

Black: Anytime there is a change, there’s a chance for new legislation, just as when the last new administration came in. The Obama administration focused on the stimulus act, which created an important construct around digitizing the entire healthcare system.

I hope they continue focusing on cancer, on precision medicine, which are natural stepping stones once you’ve got the interoperability done, once you’ve got the consumer connected.

I’m sure the MACRA rules will stay intact. We don’t see that slowing down.

Black: Yes. It’s not a major meter mover from a financial standpoint. But it allows us to work with our clients on systems that we’ve been working with them on for a long time. 2017 will be a big year for putting those systems in place.

There are some suppliers who have stated they won’t be compliant with all future regulatory changes. That presents an opportunity to secure new clients. We will actively pursue that business as well.

MH: You’ve bet big on population health management. Yet new HHS Secretary Tom Price seems to emphasize physician autonomy.

Black: He will make sure if we add more regulatory changes to the workflow, we’ll take time to understand what impact it will have to their practices. My crystal ball says there will be more practical testing before we make it mandatory. He’s going to try to do everything he can to minimize the work impact to the physician community.